WallStreetZenWallStreetZen

NYSE: EVMN
Evommune Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EVMN

Based on 5 analysts offering 12 month price targets for Evommune Inc

Min Forecast
$8.00+4.85%
Avg Forecast
$21.00+175.23%
Max Forecast
$28.00+266.97%

Should I buy or sell EVMN stock?

Based on 7 analysts offering ratings for Evommune Inc.

Buy
Strong Buy
1 analysts 14.29%
Buy
3 analysts 42.86%
Hold
3 analysts 42.86%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although EVMN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates EVMN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their EVMN stock forecasts and price targets.

EVMN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-11-13
lockedlocked$00.00+00.00%2026-10-12
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-09-09
Morgan Stanley
Bottom 3%
3
Strong BuyMaintains$26.00+224.19%2026-06-30
William Blair
Bottom 10%
10
HoldDowngradesN/AN/A2026-06-29

1 of 1

Forecast return on equity

Is EVMN forecast to generate an efficient return?

Company
-73.77%
Industry
33.13%
Market
162.32%
EVMN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EVMN forecast to generate an efficient return on assets?

Company
-66.63%
Industry
20.56%
EVMN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EVMN earnings per share forecast

What is EVMN's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
-$3.34-126.19%
Avg 2 year Forecast
-$3.67-128.72%
Avg 3 year Forecast
-$3.47-127.21%

EVMN revenue forecast

What is EVMN's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0
EVMN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EVMN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EVMN$8.02$21.00+161.85%Buy
IPSC$1.63$8.00+390.80%Buy
CABA$1.33$9.00+576.69%Buy
ALLO$0.83$6.00+625.51%Buy
OCGN$0.87$10.25+1,072.77%Strong Buy
View Top Biotech Stocks

Evommune Stock Forecast FAQ

Is Evommune Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NYSE: EVMN) stock is to Buy EVMN stock.

Out of 7 analysts, 1 (14.29%) are recommending EVMN as a Strong Buy, 3 (42.86%) are recommending EVMN as a Buy, 3 (42.86%) are recommending EVMN as a Hold, 0 (0%) are recommending EVMN as a Sell, and 0 (0%) are recommending EVMN as a Strong Sell.

If you're new to stock investing, here's how to buy Evommune stock.

What is EVMN's earnings growth forecast for 2026-2028?

(NYSE: EVMN) Evommune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.79%.

Evommune's earnings in 2026 is -$94,668,000.On average, 15 Wall Street analysts forecast EVMN's earnings for 2026 to be -$121,273,725, with the lowest EVMN earnings forecast at -$131,950,864, and the highest EVMN earnings forecast at -$109,366,283. On average, 15 Wall Street analysts forecast EVMN's earnings for 2027 to be -$133,017,853, with the lowest EVMN earnings forecast at -$155,424,603, and the highest EVMN earnings forecast at -$84,596,915.

In 2028, EVMN is forecast to generate -$125,998,958 in earnings, with the lowest earnings forecast at -$156,491,591 and the highest earnings forecast at -$73,545,967.

What is EVMN's revenue growth forecast for 2026-2028?

(NYSE: EVMN) Evommune's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.

Evommune's revenue in 2026 is $10,000,000.On average, 12 Wall Street analysts forecast EVMN's revenue for 2026 to be $0, with the lowest EVMN revenue forecast at $0, and the highest EVMN revenue forecast at $0. On average, 12 Wall Street analysts forecast EVMN's revenue for 2027 to be $0, with the lowest EVMN revenue forecast at $0, and the highest EVMN revenue forecast at $0.

In 2028, EVMN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is EVMN's forecast return on assets (ROA) for 2026-2029?

(NYSE: EVMN) forecast ROA is -53.9%, which is lower than the forecast US Biotechnology industry average of 19.93%.

What is EVMN's Price Target?

According to 5 Wall Street analysts that have issued a 1 year EVMN price target, the average EVMN price target is $21.00, with the highest EVMN stock price forecast at $28.00 and the lowest EVMN stock price forecast at $8.00.

On average, Wall Street analysts predict that Evommune's share price could reach $21.00 by Oct 12, 2027. The average Evommune stock price prediction forecasts a potential upside of 161.85% from the current EVMN share price of $8.02.

What is EVMN's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: EVMN) Evommune's current Earnings Per Share (EPS) is $5.54. On average, analysts forecast that EVMN's EPS will be -$3.34 for 2026, with the lowest EPS forecast at -$3.64, and the highest EPS forecast at -$3.01. On average, analysts forecast that EVMN's EPS will be -$3.67 for 2027, with the lowest EPS forecast at -$4.28, and the highest EPS forecast at -$2.33. In 2028, EVMN's EPS is forecast to hit -$3.47 (min: -$4.31, max: -$2.03).

What is EVMN's forecast return on equity (ROE) for 2026-2029?

(NYSE: EVMN) forecast ROE is -58.63%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.